1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.

Article Details

Citation

Copy to clipboard

Hou DR, Alam S, Kuan TC, Ramanathan M, Lin TP, Hung MS

1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1022-5. doi: 10.1016/j.bmcl.2008.11.029. Epub 2008 Nov 14.

PubMed ID

19095444 [ View in PubMed

]

Abstract

This letter reports the new entry of novel 1,2,3-triazole derivatives as CB1 receptor antagonists. The design, synthesis and biological evaluation of N1 and N2 substituted 1,2,3-trizoles are described. The N2 substituted, symmetrical 1,2,3-triazoles are more potent ligands than the unsymmetrical analogues. The in vitro activity of these triazoles is further improved by inserting a methylene group between the central core and the carbonyl side chain. The most potent antagonists prepared in this series (IC(50)<20 nM) are the triazoles containing benzyl amides. These triazoles also show excellent selectivity between CB1 and CB2 receptors (IC(50)>10 microM for CB2; CB2/CB1>1000).

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Rimonabant	Cannabinoid receptor 1	IC 50 (nM)	15	N/A	N/A	Details
Rimonabant	Cannabinoid receptor 1	EC 50 (nM)	18.2	N/A	N/A	Details
Rimonabant	Cannabinoid receptor 1	Ki (nM)	5.6	N/A	N/A	Details